Evonik expects second-quarter adjusted EBITDA of €600 million to €650 million, based on preliminary figures. At the midpoint of that range, the result would be 23% above the €509 million reported in the second quarter of 2025. In early May, the company had forecast second-quarter earnings of at least €550 million.

The company said higher sales volumes, pricing and continuing cost reductions contributed to the improved performance. In its Advanced Technologies segment, Evonik said supply-chain disruption affecting Asian competitors with raw material limitations also supported results.

Evonik said it expects those supply-chain effects to weaken later in the year as global marine shipping stabilizes following the reopening of the Strait of Hormuz. The company said it expects positive momentum in its Animal Nutrition segment to continue into the third quarter.

For the first half of 2026, Evonik expects adjusted EBITDA of approximately €1.1 billion. It maintained its goal of a cash-conversion rate of about 40% for the year and said second-quarter free cash flow is expected to be significantly better than the prior-year period.

The company also said it is continuing its “Evonik Tailor Made” transformation program, which includes efficiency and structural measures across administration and operating units. Evonik previously said it plans to cut 2,800 jobs between 2024 and 2026, with an additional reduction of about 3,200 positions planned from 2027 through 2029.

Evonik is scheduled to publish final second-quarter results on Aug. 4, 2026.